Mineralys Therapeutics has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $120 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Mineralys Therapeutics is raising $120,000,000.00 in new funding. About Mineralys Therapeutics: Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Lorundrostat is a highly selective aldosterone synthase inhibitor developed to address abnormally elevated aldosterone, an underlying cause prevalent in at least 25% of all hypertensive patients. Lorundrostat has demonstrated selectivity for the reduction of aldosterone with no cortisol suppression. Lorundrostat selectivity holds the potential for targeted treatment of blood pressure in hypertension patients with abnormally elevated aldosterone
To learn more about Mineralys Therapeutics, visit http://mineralystx.com/
Contact:
Jon Congleton, Chief Executive Officer
888-378-6240
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.